News | Radiation Therapy | January 03, 2017

NCCN Guidelines Recommend Y-90 Microspheres for Metastatic Colorectal Cancer Treatment

Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres

January 3, 2017 — Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an appropriate option in patients with liver dominant, chemotherapy resistant colorectal disease (mCRC). This recommendation places SIR-Spheres Y-90 resin microspheres at the same designation as the recommended mCRC systemic chemotherapeutic regimens.

The new NCCN Guidelines are available online at https://www.nccn.org/professionals/physician_gls/f_guidelines.asp

According to Sirtex Americas CEO Kevin Richardson, the company has positive signals in the first-line setting from the results to-date of the SIRFLOX study1 and expects results from the SIRFLOX, FOXFIRE and FOXFIRE Global studies in the first half of 2017.

These findings are also supported by the landmark MORE study2, a large retrospective analysis conducted in the United States with SIR-Spheres Y-90 resin microspheres in more than 600 mCRC patients. The MORE study helped to increase the understanding of SIRT as a treatment option for patients who have failed multiple lines of chemotherapy, while highlighting the positive aspects of the safety and efficacy of the protocol for patients of all ages.

“Clinical research has shown that SIRT brings patients with colorectal liver metastases improved and prolonged quality of life,” said lead investigator of the MORE study, Andrew S. Kennedy, M.D., FACRO, director, radiation oncology research at Sarah Cannon Research Institute, Nashville, Tenn. “We look forward to expanding access to this outpatient procedure, which has demonstrated minimal side effects, to improve outcomes for this population of patients and advance the standard of care.”

SIR-Spheres Y-90 resin microspheres are the first and only microspheres with U.S. Food and Drug Administration (FDA) premarket approval (PMA) for colorectal cancer that has metastasized to the liver.3

For more information, visit www.sirtex.com.

References

1. van Hazel GA, Heinemann V, Sharma NK et al. SIRFLOX: Randomized Phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2016; 34: 1723–1731.

2. Kennedy AS, Ball D, Cohen SJ et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. Journal of Gastrointestinal Oncology. 2015; 6: 134–142

3. SIR-Spheres microspheres (Yttrium-90 Microspheres) Product Information. Available at: www.sirtex.com/us/clinicians/package-insert/. Assessed on December 8, 2016.

 

Related Content

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit
Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by an AI algorithm from RaySearch and is the subject of the No. 2 video on the list. Deep learning in radiology and radiation oncology.

Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by a machine learning algorithm from RaySearch and is the subject of the No. 2 video on the list. 

Feature | December 30, 2019
Here are the top 20 best performing videos posted on the Imaging Technology News website (ITN) from the past year, ba
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...
Beamscan MR for ViewRay MRIdian and for Elekta Unity

Beamscan MR for ViewRay MRIdian and for Elekta Unity

News | Radiation Therapy | December 23, 2019
December 23, 2019 — The Beamscan MR motorized 3-D...
radiation exposure triggers an immune response in the brain that severs connections between nerve cells
News | Clinical Trials | December 17, 2019
December 17, 2019 — One of the potentially life-altering side effects that patients experience after...
In connection with the collaboration, Elekta has committed to make an investment in ViewRay representing approximately 9.9 percent of the shares of ViewRay’s common stock
News | Radiation Therapy | December 13, 2019
December 13, 2019 — Elekta announced that the company has sign
UFHPTI expands its proton therapy capacity and treatment range with the Proteous One
News | Radiation Therapy | December 12, 2019
December 12, 2019 — IBA (Ion Beam Applications SA) announced that